Celsa C, Cabibbo G, Pinato DJ. Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment. Hepatology 2024 Dec 25. doi: 10.1097/HEP.0000000000001217.
PMID: 39724005